58: Beacon-BTC: A Phase 3 Randomized Study Evaluating Nanvuranlat in Patients with Previously Treated Advanced Biliary Tract Cancer

Eric K Rowinsky, Ghassan K Abou-Alfa, Masafumi Ikeda, Makoto Ueno, Milind Javle, Junji Furuse · 2026

Read 58: Beacon-BTC: A Phase 3 Randomized Study Evaluating Nanvuranlat in Patients with Previously Treated Advanced Biliary Tract Cancer by Eric K Rowinsky, Ghassan K Abou-Alfa, Masafumi Ikeda, Makoto Ueno, Milind Javle, Junji Furuse (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13287884.txt.

Description

Eric K Rowinsky and colleagues outline a phase 3 trial of nanvuranlat for advanced bile duct cancer in a 2026 abstract. Nanvuranlat blocks a transporter that feeds amino acids to tumor cells. An earlier phase 2 study found longer time without disease growth in heavily treated patients. People with advanced bile duct cancer have few good options after first treatment fails, so a confirmatory trial matters.

The trial, called Beacon-BTC, randomly assigns patients who had one prior therapy. In part A, 120 patients receive one of three nanvuranlat infusion schedules or a doctor-chosen standard regimen. Data from part A will pick the best schedule for part B, where 360 patients get nanvuranlat or standard care. Survival is the main outcome, with tumor response and safety also tracked. Recruitment began in January 2026, and no results are available yet.

Catalog record

CREATOREric K Rowinsky, Ghassan K Abou-Alfa, Masafumi Ikeda, Makoto Ueno, Milind Javle, Junji Furuse
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE2 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13287884

Browse the full library · About the Tower of Babel